First, they have to be diagnosed with PC to then be curatively treated, have a PSA relapse that may or may not be treated with salvage radiation therapy or surgical therapy, and thereafter have second PSA relapse and then be put on GnRH in order to develop CRPC to be included in the studied cohort. The gene discussed is GNRH1; the disease is pachyonychia congenita.